Quick answer
TB-500 is a synthetic peptide derived from thymosin beta-4 (Tβ4), the 43-residue actin-sequestering protein found in nearly every mammalian cell type. In the laboratory it is used to probe actin regulation, cell migration, endothelial tube formation and tissue-remodeling endpoints. Its proposed mechanism is a direct protein–protein interaction with monomeric G-actin rather than signaling through a cell-surface receptor.
- Parent protein: Tβ4, 43 amino acids, N-terminally acetylated, about 4.96 kDa
- Key motif: a short actin-binding stretch (LKKTET, residues 17–22 of Tβ4)
- Typical models: endothelial, keratinocyte and fibroblast cultures; scratch-wound and tube-formation assays; ex-vivo and rodent tissue models
- Identity caution: “TB-500” is used for different molecular forms, so confirm sequence and mass on the certificate of analysis
- Bench math: mg in vial ÷ mL of diluent = mg/mL; use the reconstitution calculator
For laboratory research use only; not for human consumption. This guide gathers what is known about the structure, history, mechanism, preclinical model systems and handling of TB-500 so that experiments can be designed around the actual molecule. Research material is listed on the TB-500 product page, and a paired formulation is described under the BPC-157 + TB-500 research stack.
What TB-500 is
TB-500 is a synthetic peptide built to reproduce the biology of thymosin beta-4, one of the most abundant intracellular actin-binding proteins in mammals. Tβ4 is present at high concentration in platelets and wound fluid and across many tissue types, and its defining biochemical role is sequestering monomeric G-actin, which places it directly inside the pathways that control how the cytoskeleton is assembled. Because the cytoskeleton underlies nearly every form of directed cell movement, laboratories interested in migration, angiogenesis and tissue remodeling use Tβ4-derived peptides as probes of those processes in defined systems.
Producing the peptide synthetically gives researchers a consistent, scalable and well-characterized reagent, without extraction from tissue. As a standalone compound it also lets an experiment isolate its own contribution to endpoints such as angiogenesis and migration, rather than attributing them to a combination. When it is studied alongside BPC-157, the question is usually whether the two peptides are additive, independent or overlapping; see the BPC-157 versus TB-500 comparison.
Terminology and reagent identity
TB-500 and full-length thymosin beta-4 are sometimes discussed as if they were synonyms, but experimental reports should state the exact sequence and molecular form used. A fragment can preserve an actin-related motif without reproducing every interaction of the 43-residue parent, and that difference affects molecular weight, purity analysis, stability and the conclusions that a model can support. The table summarizes the distinction. Because the label alone does not settle which form a vial contains, verify the supplier specification and the analytical documentation before comparing results across publications or batches, and avoid attributing observations made with a fragment reagent to intact endogenous Tβ4.
| Feature | Full-length thymosin beta-4 | Shorter actin-motif fragments |
|---|---|---|
| Length | 43 residues | A short stretch around the actin-binding motif |
| Approximate mass | About 4,963 Da (acetylated N-terminus) | Roughly 1 kDa or less, depending on the fragment |
| Actin-binding region | Present (LKKTET, residues 17–22) | Retained by design |
| Other interactions of the parent | May be present | Not necessarily retained |
| Analytical signature | Distinct on HPLC and mass spectrometry | Resolves clearly from the intact 43-mer |
Discovery and history
The story begins decades before TB-500 existed, with the isolation of a family of small acidic polypeptides from thymic tissue extracts in the 1960s and 1970s. Those extracts were studied within an immune-signaling framework, and one component did not fit neatly into it. The complete amino acid sequence of the bovine peptide, thymosin beta-4, was reported in 1981 by Low, Hu and Goldstein, and the protein proved to be present in unusually high concentrations in nearly every mammalian cell type rather than being confined to the thymus.
The decisive biochemical step followed: Safer and colleagues showed in 1991 that Tβ4 is the same entity as an actin-sequestering peptide previously characterized in other tissues. That reframed the molecule from a thymic curiosity into a major regulator of the monomeric actin pool, relevant to cell shape, division and motility.
From basic biology to tissue-remodeling research
In the following decades, Tβ4’s association with wound-related biology drew sustained academic and pharmaceutical interest. Work in the late 1990s reported that Tβ4 promoted endothelial cell differentiation and angiogenesis and accelerated dermal wound closure in animal models, and a 2004 study in Nature linked Tβ4 to cardiac cell migration and survival in a mouse model through integrin-linked kinase. Development programs explored synthetic and recombinant versions across dermal, ocular and cardiac tissue research. Those programs set the biological rationale on which TB-500 research now draws, centered on the same actin-sequestering activity.
A parallel track with BPC-157
TB-500 research has often intersected with the study of BPC-157, a peptide investigated for tissue-related biology through a different mechanism. The two are commonly discussed together; see BPC-157 and TB-500 combination research for how designs that pair them are structured, and the discovery and history article for the standalone account.
Chemical structure and synthesis
Sequence and structural features
The Tβ4 sequence is acidic and highly conserved across mammals, and, notably for a peptide this small, largely unstructured in solution rather than folding into a fixed tertiary shape. Its function depends less on a rigid fold than on a specific stretch of residues that binds actin. The natural protein is acetylated at its N-terminus, a modification associated with resistance to aminopeptidase degradation, and synthetic preparations are typically produced to reflect that feature since an unprotected N-terminus can shorten a peptide’s usable stability window in solution. The peptide has no disulfide bonds, which simplifies certain analytical aspects.
Solid-phase synthesis
TB-500 is produced by solid-phase peptide synthesis, in which amino acids are added one at a time to a resin-bound chain while protecting groups control which reactive sites participate at each step. A full 43-residue sequence is long by the standards of research peptides, so coupling efficiency, cleavage and purification all require careful control to prevent truncated or deletion sequences from accumulating alongside the full-length product.
Purification and verification
After synthesis the crude peptide is purified by reversed-phase HPLC to separate the target sequence from by-products and verified by mass spectrometry to confirm that the measured mass matches the expected value. This two-step verification is standard and explained in HPLC versus mass spectrometry and TB-500 purity testing. Because molecular weight is the clearest marker separating the intact 43-mer from shorter fragments, mass confirmation is the first check when the form of the reagent is in doubt. Further detail is in the chemical structure and synthesis article.
Structural basis for its research role
The actin-binding region is what connects TB-500’s chemistry to its use in migration and angiogenesis research. The peptide is not a receptor ligand with a defined pharmacophore in the usual sense; its activity is attributed to a short linear motif that engages G-actin.
Mechanism of action
Actin sequestration and the monomer pool
Tβ4 is a principal regulator of G-actin, the monomeric form of actin, and is studied for sequestering actin monomers and thereby influencing the balance between monomer and filament. By binding G-actin it maintains a reservoir of monomers that can be mobilized for rapid, localized polymerization when a cell needs to extend a leading edge or migrate. That buffering role is why the peptide is examined in the context of dynamic cytoskeletal remodeling rather than static structure. The standalone mechanism of action article develops the same logic.
From actin availability to directed movement
The balance shift is not a passive side effect. It is a control point cells use to extend lamellipodia during migration. Endothelial cells cannot migrate, elongate or form capillary-like structures without extensive actin remodeling, which is why researchers investigating vessel formation keep returning to peptides built around the Tβ4 sequence. TB-500 is therefore used to ask how actin availability affects endothelial and epithelial cell movement in assays designed for that purpose; see TB-500 in angiogenesis research.
Distinct from receptor agonists
Unlike peptides that act through cell-surface receptor signaling, TB-500’s proposed action is a direct interaction with actin. This is a key conceptual distinction when interpreting readouts: there is no receptor to knock out, no cAMP or arrestin readout to measure, and concentration–response behavior depends on cell type and on how much extracellular peptide actually reaches intracellular actin.
Separating direct and downstream effects
Changes in migration or network formation are downstream phenotypes and do not by themselves demonstrate direct actin binding. Mechanistic designs can pair biochemical binding measurements with imaging of filament organization, migration assays and perturbation of actin polymerization. Sequence controls, such as a version of the peptide with the actin-binding motif altered, test whether the proposed region is required. Cell viability and proliferation controls are also necessary, since either can change an apparent migration endpoint without altering cytoskeletal motility, and time-resolved imaging helps separate these possibilities. It is equally important to distinguish the synthetic reagent from full-length Tβ4, because the parent may have interactions that a shorter reagent does not retain. This layered approach prevents a complex remodeling phenotype from being reduced to a single unverified molecular event.
Preclinical research findings
Preclinical work on TB-500 follows the usual progression from reduced, controlled systems toward more complex models, with each tier answering a different question. Concentrations in vitro are set by assay design, and conclusions are tier-specific: cell-based results do not establish tissue-level outcomes, and animal-model results remain bounded to the species, strain and protocol used.
| Model tier | Examples | Typical endpoints | What it can and cannot show |
|---|---|---|---|
| Cultured cells | Endothelial cells, keratinocytes, fibroblasts | Migration speed, cytoskeletal reorganization, tube or sprout formation | Isolates one variable at a defined concentration; no tissue architecture |
| Scratch-wound assays | Cell monolayers closing a defined gap | Rate of gap closure | Closure can reflect migration, proliferation or adhesion; needs proliferation controls |
| Tube-formation assays | Endothelial cells on a matrix | Tube length, branch points | Surrogate of vessel organization in a 2D/3D matrix |
| Ex-vivo and organotypic models | Excised tissue, aortic-ring-type sprouting | Vessel sprouting into matrix, directed cell movement | More tissue complexity, still controlled conditions |
| Rodent and other animal models | Cardiac, dermal and corneal tissue models | Structural recovery and tissue-response endpoints | Systemic biology; results are model-specific |
Cell-based research
The earliest tier uses endothelial cells, keratinocytes, fibroblasts and similar models to examine how the peptide affects actin-dependent behaviors such as migration speed, cytoskeletal reorganization and tube or sprout formation. These assays isolate a single measurable variable, which makes them useful for dissecting mechanism before moving to more complex systems.
Tissue and ex-vivo models
A second tier uses excised tissue or organotypic culture, which retains more of the structural complexity of a real tissue while still allowing controlled conditions. These models matter for angiogenesis and cell migration because vessel sprouting and directed cell movement behave differently in three-dimensional matrix than on a flat monolayer.
Animal-model research
Rodent and other animal models are the most complex tier in common use, allowing whole-organism tissue-response endpoints such as structural recovery in cardiac, dermal or corneal models. This is also the tier where the actin-related mechanism of TB-500 is most often compared against the distinct mechanism of BPC-157, to ask whether the two produce additive, independent or overlapping effects. The published animal literature includes reports of accelerated dermal wound closure and of cardiac cell migration and survival after Tβ4 exposure in mice, as noted in the references below; these concern the parent protein and should not be assumed to transfer to a differently defined reagent.
Interpreting a migration result
Faster closure of a scratch assay can reflect migration, proliferation, altered adhesion or a combination. Parallel proliferation controls, live-cell imaging and actin-organization measurements identify which component changed. These controls make a standalone experiment far more informative before TB-500 is compared with other compounds. Across every tier, reliability also depends on the starting material: purity, correct sequence identity and consistent reconstitution all determine whether an experiment measures the peptide’s biology or an artifact of a poorly characterized sample. See also TB-500 preclinical research and the thymosin beta-4 research overview.
Handling, reconstitution and storage
Reconstituting TB-500 means moving from a stable lyophilized state into a liquid stock without damaging the peptide. The chemistry is simple but the details matter for reproducibility. Use the peptide calculator for any vial, and see the dedicated TB-500 reconstitution and storage article and the general lyophilized-peptide guide. For a fully worked bench example with the same order of steps, see the retatrutide reconstitution protocol; the technique carries over.
Preparing the stock solution
- Allow the sealed vial to reach room temperature before opening so condensation does not form inside.
- Add bacteriostatic water slowly down the inner wall of the vial, not directly onto the powder, to avoid localized turbulence.
- Swirl gently. Vigorous shaking introduces mechanical stress and can promote aggregation.
- Use or store the solution promptly rather than leaving it at room temperature.
- Label with date, diluent, volume and mg/mL.
Because TB-500 relates to an actin-binding region, preserving its intended conformation matters for whether downstream cell assays reflect the biology under study rather than degraded starting material.
Illustrative concentration table
The table assumes a hypothetical 5 mg vial of the intact 43-residue form (about 4,963 g/mol). If the certificate of analysis lists a different mass, recompute the molar column with that value, and correct for net peptide content for quantitative work.
| Diluent added | Concentration | Molar concentration |
|---|---|---|
| 1 mL | 5 mg/mL | 1,007 µM |
| 2 mL | 2.5 mg/mL | 504 µM |
| 2.5 mL | 2 mg/mL | 403 µM |
| 5 mL | 1 mg/mL | 201 µM |
Storage
The unopened lyophilized vial keeps best refrigerated or frozen, protected from light and moisture. After reconstitution, store the solution refrigerated for near-term use, or divide it into single-use aliquots and freeze them if the project runs for weeks. Repeated freeze–thaw cycling is one of the most common sources of peptide degradation and applies to TB-500 as to any other lyophilized peptide. Low-binding tubes help keep nominal and actual concentrations aligned at low stock concentrations. Where TB-500 is studied alongside BPC-157, many laboratories standardize water source, swirl technique and aliquoting schedule across both arms so that handling is a fixed variable; see BPC-157 + TB-500 blend reconstitution for the paired case. General principles are in storing research peptides.
Purity, COA and quality
Reproducibility in actin-biology assays depends on knowing exactly what is in the vial. For a 43-residue peptide, truncated and deletion sequences are the main impurity class, so a summary purity percentage should be backed by the chromatogram itself. A sensible routine: match the batch number on the vial to its certificate of analysis; inspect the HPLC trace; confirm that the measured mass corresponds to the intended molecular form (the intact 43-mer and shorter fragments are easy to distinguish by mass); and log batch, storage history and preparation date with the experimental record. Batch documents are on the CoA page, and the reading of them is covered in how to read a COA and understanding HPLC purity. Peptide-specific analysis is described in TB-500 purity testing, and the combined formulation is discussed in BPC-157 and TB-500 third-party testing. For sourcing criteria see where to buy TB-500 for research, and for the material itself the TB-500 product page.
Related compounds and comparisons
- BPC-157: investigated for tissue-related biology through a mechanism distinct from actin sequestration. See BPC-157 versus TB-500 and the combination research overview.
- Combined research material: the BPC-157 + TB-500 stack supplies both peptides for parallel handling, and BPC-157 is listed separately.
When comparing TB-500 with any other peptide, match the assay, the cell type, the time course and the proliferation controls, because the readouts most often used for it (migration and sprouting) are sensitive to all of them.
Frequently asked questions
What is TB-500 in relation to thymosin beta-4?
TB-500 is a synthetic peptide derived from thymosin beta-4 (Tβ4), the naturally occurring 43-residue actin-binding protein. Reports use the name for different molecular forms, so the exact sequence and mass should be confirmed on the certificate of analysis.
What is the proposed mechanism?
Actin regulation. Tβ4-derived sequences are studied for sequestering monomeric G-actin, shifting the monomer–filament balance that cells use to migrate and remodel. This is a direct protein–protein interaction rather than receptor signaling.
Which assays are most used in TB-500 research?
Scratch-wound migration assays, endothelial tube-formation assays, ex-vivo sprouting models and rodent tissue models, each tracking measurable endpoints such as closure rate, tube length or sprout density.
Why must scratch-assay results be interpreted carefully?
Faster gap closure can result from migration, proliferation, altered adhesion or a mix. Proliferation controls, live-cell imaging and actin-organization measurements are needed to identify which process changed.
How is TB-500 distinguished from full-length thymosin beta-4 analytically?
By molecular weight. The intact 43-residue protein is about 4,963 Da, whereas shorter fragments are far lighter, so the two resolve distinctly by HPLC and mass spectrometry.
How is it commonly studied alongside BPC-157?
The two peptides act through different proposed mechanisms, so laboratories compare them or run them together to ask whether effects are additive, independent or overlapping. Handling is usually standardized across both arms.
How should lyophilized TB-500 be stored?
Sealed, cold, dry and protected from light. Allow the vial to reach room temperature before opening to avoid condensation on the powder.
How long can reconstituted stock be kept?
Refrigerate for near-term use and divide into single-use frozen aliquots for longer projects, thawing each once. Any quoted multi-week window for preserved multi-use vials reflects sterility conventions, not a TB-500-specific stability measurement.
How is the concentration of a reconstituted vial calculated?
Divide the mass of peptide by the volume of diluent. A 5 mg vial in 2 mL gives 2.5 mg/mL, which is about 504 µM for a 4,963 g/mol peptide before correcting for net peptide content.
What documentation should accompany a TB-500 lot?
A lot-specific certificate of analysis with HPLC purity and the chromatogram, plus mass-spectrometry identity matching the intended molecular form, linked to the batch number on the vial.
Research-use statement
TB-500 is supplied strictly as a laboratory reagent. For laboratory research use only; not for human consumption. Nothing in this guide is usage guidance; concentrations given are bench stock arithmetic for in-vitro work, and the findings described come from cultured cells, tissue preparations and animal models. Material is also not intended for veterinary or diagnostic purposes. Supply details are on the product page.
References
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162-1166.
- Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Grant DS, Kinsella JL, Kibbey MC, et al. Thymosin β4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-135.
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575.
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60.
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46.